Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F)(the “Company” or “Isodiol”) is pleased to announce that its subsidiary, ISO-SPORT™, has reached deals with two United Kingdom-based mixed martial arts retailers to sell the CBD Performance Products. Acclaimed as being two of the U.K.’s top online sources of mixed martial arts supplies, LondonFightStore.com and Grapplestore.co.uk have officially launched sales of the products to their clients.
London Fight Store is renowned for selling world-class equipment and apparel for boxing, MMA, Muay Thai, and Brazilian Jiu-Jitsu. London Fight Store is also proud sponsors of Cage Warriors along with Iso-Sport.
Grapplestore is the U.K.’s largest online grappling store and has been trading online for over five years. The Company is run by dedicated Brazilian Jiu-Jitsu enthusiasts and fighters offering a wide range of GIs and accessories at great prices and fast delivery with the best customer service possible.
Graham Boylan, VP for Business Development for Iso-Sport Europe comments, “Striking a deal with Grapplestore and London Fight Store is great news for our U.K. customers and Iso-Sport. Our biggest request to date from Iso-Sport European customers has been a need for easier availability and these two companies can fully cater to those needs.”
“Iso-Sport’s agreement with both retailers continues the long-standing goal of Isodiol to further expand into European markets,” said CEO of Isodiol, Marcos Agramont. “With the company’s established presence in the U.K. through BSPG Labs, Isodiol plans to continue expanding its operations and distribution of its CBD brands and specialized product lines to consumers throughout Europe.”
About Isodiol International Inc.
Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer products and solutions.
Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.